Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2012

01-03-2012 | Original article

In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging

Authors: Mauro Provinciali, Alessandra Barucca, Elisa Pierpaoli, Fiorenza Orlando, Sara Pierpaoli, Arianna Smorlesi

Published in: Cancer Immunology, Immunotherapy | Issue 3/2012

Login to get access

Abstract

Experimental evidence has been provided that cancer vaccines are less effective at older age than in young adults. In this study, we evaluated the possibility to recover the low effectiveness of DNA immunization against HER-2/neu increasing plasmid uptake by cells from old mice through electroporation with the aim to enhance the activation of specific immune responses. Young and old Balb/c mice received two immunizations with a pCMV-ECDTM DNA plasmid using plasmid intramuscular injection followed by electroporation (IM + E) or plasmid intramuscular injection alone (IM), and successively, they were challenged with syngeneic HER-2/neu overexpressing TUBO cells. Young mice were completely protected whereas less than 60% protection was observed in old mice after IM immunization. IM + E immunization completely protected old mice against a TUBO cell challenge. The protection was associated with increased transgene expression in the site of immunization and with the induction of both humoral and cell-mediated immunity in old mice. We conclude that the effectiveness of anticancer DNA vaccination in old ages may be improved increasing plasmid uptake and transgene expression through electroporation, suggesting the relevant role of the first steps of the immunization process in the success of cancer vaccines at older age.
Literature
2.
go back to reference Quaglino E, Rovero S, Cavallo F, Musiani P, Amici A, Nicoletti G et al (2002) Immunological prevention of spontaneous tumors: a new prospect? Immunol Lett 80:75–79PubMedCrossRef Quaglino E, Rovero S, Cavallo F, Musiani P, Amici A, Nicoletti G et al (2002) Immunological prevention of spontaneous tumors: a new prospect? Immunol Lett 80:75–79PubMedCrossRef
3.
go back to reference Cavallo F, Forni G (2009) Recent advances in cancer immunotherapy with an emphasis on vaccines. Exp Rev Vaccines 8:25–28CrossRef Cavallo F, Forni G (2009) Recent advances in cancer immunotherapy with an emphasis on vaccines. Exp Rev Vaccines 8:25–28CrossRef
4.
go back to reference Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15:48–51PubMedCrossRef Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15:48–51PubMedCrossRef
5.
go back to reference Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ et al (1997) Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049–1058PubMedCrossRef Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ et al (1997) Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049–1058PubMedCrossRef
6.
go back to reference Provinciali M, Smorlesi A (2005) Immunoprevention and immunotherapy of cancer in aging. Cancer Immunol Immunother 54:93–106PubMedCrossRef Provinciali M, Smorlesi A (2005) Immunoprevention and immunotherapy of cancer in aging. Cancer Immunol Immunother 54:93–106PubMedCrossRef
8.
go back to reference Provinciali M, Smorlesi A, Donnini A, Bartozzi B, Amici A (2003) Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 21:843–848PubMedCrossRef Provinciali M, Smorlesi A, Donnini A, Bartozzi B, Amici A (2003) Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 21:843–848PubMedCrossRef
9.
go back to reference Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E et al (2004) Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice. Cancer Res 64:2858–2863PubMedCrossRef Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E et al (2004) Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice. Cancer Res 64:2858–2863PubMedCrossRef
10.
go back to reference Smorlesi A, Papalini F, Amici A, Orlando F, Pierpaoli S, Mancini C et al (2006) Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24:1766–1775PubMedCrossRef Smorlesi A, Papalini F, Amici A, Orlando F, Pierpaoli S, Mancini C et al (2006) Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24:1766–1775PubMedCrossRef
11.
go back to reference Rivnay B, Globerson A, Shinitzky M (1979) Viscosity of lymphocyte plasma membrane in aging mice and its possible relation to serum cholesterol. Mech Ageing Dev 101:71–79CrossRef Rivnay B, Globerson A, Shinitzky M (1979) Viscosity of lymphocyte plasma membrane in aging mice and its possible relation to serum cholesterol. Mech Ageing Dev 101:71–79CrossRef
12.
go back to reference Rivnay B, Bergman S, Shinitzky M, Globerson A (1980) Correlation between membrane viscosity, serum cholesterol, lymphocyte activation and aging in man. Mech Ageing Dev 12:119–126PubMedCrossRef Rivnay B, Bergman S, Shinitzky M, Globerson A (1980) Correlation between membrane viscosity, serum cholesterol, lymphocyte activation and aging in man. Mech Ageing Dev 12:119–126PubMedCrossRef
13.
go back to reference Provinciali M, Di Stefano G, Fabris N (1992) Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional 51CR release assay. J Immunol Meth 155:19–24CrossRef Provinciali M, Di Stefano G, Fabris N (1992) Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional 51CR release assay. J Immunol Meth 155:19–24CrossRef
14.
go back to reference Bryant J, Day R, Whiteside T, Herberman RB (1992) Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 146:91–96PubMedCrossRef Bryant J, Day R, Whiteside T, Herberman RB (1992) Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 146:91–96PubMedCrossRef
15.
go back to reference Barber DL, Wherry EJ, Ahmed R (2003) Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 171:27–31PubMed Barber DL, Wherry EJ, Ahmed R (2003) Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 171:27–31PubMed
16.
go back to reference Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A et al (1995) Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155:3112–3123PubMed Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A et al (1995) Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155:3112–3123PubMed
17.
go back to reference Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E et al (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133–5142PubMed Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E et al (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133–5142PubMed
18.
go back to reference Amici A, Smorlesi A, Noce G, Santoni G, Cappelletti P, Capparuccia L et al (2000) DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 7:703–706PubMedCrossRef Amici A, Smorlesi A, Noce G, Santoni G, Cappelletti P, Capparuccia L et al (2000) DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 7:703–706PubMedCrossRef
19.
go back to reference George AJT, Ritter MA (1996) Thymic involution with ageing: obsolescence or good housekeeping? Immunol. Today 17:267–272 George AJT, Ritter MA (1996) Thymic involution with ageing: obsolescence or good housekeeping? Immunol. Today 17:267–272
20.
go back to reference Fabris N, Mocchegiani E, Provinciali M (1997) Plasticity of neuro-endocrine-thymus interactions during ageing. Exp Gerontol 32:415–430PubMedCrossRef Fabris N, Mocchegiani E, Provinciali M (1997) Plasticity of neuro-endocrine-thymus interactions during ageing. Exp Gerontol 32:415–430PubMedCrossRef
22.
go back to reference Provinciali M (2009) Immunosenescence and cancer vaccines. Cancer Immunol Immunother 58:1959–1967PubMedCrossRef Provinciali M (2009) Immunosenescence and cancer vaccines. Cancer Immunol Immunother 58:1959–1967PubMedCrossRef
23.
go back to reference Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of cancer gene therapy in ageing: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7:624–632PubMedCrossRef Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of cancer gene therapy in ageing: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7:624–632PubMedCrossRef
24.
go back to reference Lustgarten J, Dominguez A, Thoman M (2004) Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 173:4510–4515PubMed Lustgarten J, Dominguez A, Thoman M (2004) Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 173:4510–4515PubMed
25.
go back to reference Chapman HA Jr, Hibbs JB Jr (1977) Modulation of macrophage tumoricidal capability by components of normal serum: a central role for lipid. Science 197:282–295PubMedCrossRef Chapman HA Jr, Hibbs JB Jr (1977) Modulation of macrophage tumoricidal capability by components of normal serum: a central role for lipid. Science 197:282–295PubMedCrossRef
26.
go back to reference Provinciali M, Fabris N, Pieri C (1990) Improvement of Natural Killer cell activity by in vitro active lipids (AL721) administration in old mice. Mech Ageing Dev 52:245–254PubMedCrossRef Provinciali M, Fabris N, Pieri C (1990) Improvement of Natural Killer cell activity by in vitro active lipids (AL721) administration in old mice. Mech Ageing Dev 52:245–254PubMedCrossRef
27.
go back to reference Sharma S, Dominguez A, Lustgarten J (2006) Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4–1BB. Exp Gerontol 41:78–84PubMedCrossRef Sharma S, Dominguez A, Lustgarten J (2006) Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4–1BB. Exp Gerontol 41:78–84PubMedCrossRef
Metadata
Title
In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging
Authors
Mauro Provinciali
Alessandra Barucca
Elisa Pierpaoli
Fiorenza Orlando
Sara Pierpaoli
Arianna Smorlesi
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1107-2

Other articles of this Issue 3/2012

Cancer Immunology, Immunotherapy 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine